Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
- Details
- Category: DNA RNA and Cells
- Published on Monday, 20 September 2021 18:28
- Hits: 128
TACTIC-2 marks first in-human use of TAC-T cell therapy
Phase 1/2 clinical trial will evaluate TAC01-HER2, Triumvira’s lead candidate, in patients with HER2-overexpressing solid tumors
First patient dosed at MD Anderson Cancer Center in Houston, Texas
AUSTIN, TX, USA & HAMILTON, Canada I September 20, 2021 I Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors. The company’s proprietary T cell Antigen Coupler (TAC) platform technology activates natural T cell functions differently from other cell therapies such as Chimeric Antigen Receptor T cell (CAR-T) and engineered T cell receptor therapies.
“Despite advances with CAR-T cell therapies in hematological malignancies, there remains a substantial patient population within solid tumors in need of treatments that can demonstrate prolonged safety and efficacy,” said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. “The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology. We look forward to sharing our progress with this program as we build out a pipeline of candidates targeting solid tumors.”
Triumvira’s TAC technology has the potential to empower T cells to locate and destroy tumor cells by activating the natural T cell receptor for maximal and controlled anti-tumor responses. Triumvira’s HER2-TAC engineered T cells have demonstrated superior anti-cancer properties and more favorable safety profiles in preclinical studies when compared to both CAR-T cell and standard-of-care therapies.
Triumvira’s TAC01-HER2 was manufactured using Lonza’s Cocoon® Platform, a state-of-the-art, automated and self-contained manufacturing system that offers an elegant solution to address many of the challenges of manufacturing autologous cell therapies. With this trial, Triumvira is the first company in the U.S. to dose a patient with a therapy manufactured with Lonza’s Cocoon Platform. As previously announced, Triumvira and Lonza have established a collaboration to expand the use of the Cocoon as an elegant manufacturing solution for TAC-T cell therapeutics.
TACTIC-2 is a Phase 1/2 multicenter, open-label trial designed to evaluate the safety, tolerability and efficacy of TAC01-HER2 in people with HER2-positive metastatic, advanced, unresectable solid tumors such as breast, gastric and many other cancers. The clinical trial is actively enrolling participants at MD Anderson Cancer Center in Houston, Texas, and Dana Farber Cancer Institute in Boston, Mass., and University of Chicago, Ill. and plans to enroll approximately 70 participants.
In addition to TAC01-HER2, Triumvira intends to bring multiple TAC programs directed at other promising targets in solid and liquid cancers into clinical development in the coming years. More information on Triumvira’s pipeline and programs can be found at www.triumvira.com and details on the this clinical trial can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04727151.
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is a clinical-stage company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.
For more information, please visit www.triumvira.com or send email inquiries to This email address is being protected from spambots. You need JavaScript enabled to view it..
SOURCE: Triumvira Immunologics
"tactic" - Google News
September 20, 2021 at 11:33PM
https://ift.tt/39rxL7m
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial | DNA RNA and Cells | News Channels - PipelineReview.com
"tactic" - Google News
https://ift.tt/2NLbO9d
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial | DNA RNA and Cells | News Channels - PipelineReview.com"
Post a Comment